You are here

Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link

Best Practice & Research Clinical Rheumatology, Volume 30, Issue 1, February 2016, Pages 53 - 62


In many autoimmune rheumatic diseases, there is an increased risk of cancer compared to the general population. While reasons for this increased risk have not been elucidated, it has been hypothesized that the link between cancer and autoimmunity may be bidirectional. For instance, chronic inflammation and damage from the rheumatic disease or its therapies may trigger malignant transformation; conversely, antitumor immune responses targeting cancers may become cross-reactive resulting in autoimmunity. In rare rheumatic diseases, longitudinal observational studies can play a critical role in studying these complex relationships, thereby enabling investigators to quantify the extent of cancer risk, identify unique clinical phenotypes associated with cancer, investigate the biological link between these conditions, and define optimal strategies for screening and treatment of the underlying cancer. In this review, we discuss recent data on cancer in the rheumatic diseases and suggest a research agenda to address several gaps in our current knowledge base.

Keywords: Cancer, Autoimmunity, Observational cohorts, Epidemiology.


Autoimmune conditions have long been associated with an increased risk of malignancy. While the pathogenic mechanisms underlying an increased cancer risk are not fully understood, the link between cancer and autoimmunity is likely dynamic and bidirectional in nature [1]. Multiple immune and inflammatory pathways may activate tumorigenesis, and data suggest that active, inflammatory rheumatic disease may contribute to cancer initiation and promotion. Similarly, antitumor immune responses that limit tumor growth may become cross-reactive with self-tissues resulting in autoimmunity. Given the difficulty in measuring relatively rare outcomes such as cancer in the rheumatic diseases, large longitudinal epidemiological studies are valuable for understanding the relationships between malignancy and autoimmunity. In this review, we discuss recent data on cancer in the rheumatic diseases and suggest a research agenda to address several gaps in our current knowledge base.

Mechanisms that may explain the increased risk of cancer in the autoimmune rheumatic diseases

An increased risk of cancer has been demonstrated across the broad spectrum of autoimmune rheumatic diseases. While it is beyond the scope of this article to review cancer risk in detail for all of the rheumatic diseases, Table 1 describes the magnitude of risk and specific tumor sites of concern based on the recently published meta-analyses for select diseases. A wide array of cancer types is observed, with an increased risk of both solid organ and hematologic malignancies.

Table 1

Cancer risk in the autoimmune rheumatic diseases reported in recent meta-analyses.


Disease Author (year) Pooled SIR or RR for all cancers Tumor types with increased risk
Rheumatoid arthritis Simon (2015) [2] 1.09 (1.06, 1.13) Lymphoma (Hodgkin, non-Hodgkin), lung, melanoma
Systemic lupus erythematosus Bernatsky (2013) [3] 1.14 (1.05, 1.23) Lymphoma (non-Hodgkin), lung, leukemia, thyroid
Systemic sclerosis Onishi (2013) [4] 1.41 (1.18, 1.68) Lung, liver, hematologic, bladder
Myositis Yang (2015) [5]
 Polymyositis 1.62 (1.19, 2.04) Lung, kidney, breast, lymphoma, bladder, endometrial, cervical, thyroid, brain
 Dermatomyositis 5.50 (4.31, 6.70) Ovary, breast, lung, colorectal, cervical, bladder, nasopharyngeal, esophagus, pancreas, kidney
Sjogren's syndrome Liang (2014) [6] 1.53 (1.17, 1.88) Non-Hodgkin's lymphoma, thyroid
ANCA-associated vasculitis Shang (2015) [7] 1.74 (1.37, 2.21) Nonmelanoma skin, leukemia, bladder, lymphoma, liver, lung

The relationship between cancer and the autoimmune rheumatic diseases is complex with many potential mechanisms linking the two disease states (Table 2). Malignancy may develop secondary to the rheumatic disease and its therapies. For instance, it has been proposed that chronic inflammation and tissue damage may stimulate cytokines and chemokines that further the development of malignancies through multiple mechanisms, including inducing DNA damage, inactivating tumor suppressor genes, stimulating enhanced cellular growth and survival, triggering angiogenesis, and enhancing invasion [8]. Within the rheumatic diseases, a model of inflammation-induced cancer may be particularly important in systemic lupus erythematosus (SLE; detailed later), but other data also suggest the relevance of this mechanism in Sjogren's syndrome, rheumatoid arthritis (RA), and systemic sclerosis (SSc). In Sjogren's syndrome, studies have demonstrated that salivary gland enlargement, hypocomplementemia, neutropenia, cryoglobulinemia, splenomegaly, lymphadenopathy, longer disease duration, and lymphoid organization in labial salivary gland biopsies at diagnosis are predictive of lymphoma risk [9], [10], and [11]. In RA, an increased risk of cancer and greater cancer mortality have been observed in patients who have elevated inflammatory markers [12]. In addition, a case–control study examining RA patients with lymphoma compared to RA controls suggested that long-term corticosteroid therapy, and administration of intra-articular steroids used to treat acute flares, were associated with a lower risk of lymphoma [13]. In SSc, multiple studies have demonstrated an increased risk of lung cancer in patients with interstitial lung disease, although this has not been found consistently across all studies [14] and [15]. However, data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, which enrolled >65,000 individuals, have demonstrated that baseline pulmonary scar is associated with future ipsilateral lung cancer, suggesting that this mechanism may also apply for patients with SSc [16] and [17].

Table 2

Potential mechanisms linking cancer and the autoimmune rheumatic diseases.


Proposed mechanism Example(s)
Cancer secondary to rheumatic disease
Chronic inflammation and damage from rheumatic disease 1. Sjogren's: disease activity, severity, and duration predictive of non-Hodgkin's lymphoma risk
2. RA: elevated ESR and CRP associated with increased cancer risk; long-term corticosteroid therapy associated with lower lymphoma risk
3. SSc: pulmonary scar associated with lung cancer
Cytotoxic or biologic therapies 1. Cyclophosphamide: higher cumulative doses associated with an increased risk of lymphoproliferative and bladder cancers
2. Mycophenolate: Possible increase in nonmelanoma skin cancer and CNS lymphoma
3. TNF inhibitors: an increased risk of nonmelanoma and possibly melanoma skin cancer
Inability to clear oncogenic infections SLE: risk higher for virus-associated cancers (e.g., cervical, vaginal/vulvar, and anal cancers associated with HPV)
Rheumatic disease secondary to cancer
Cancer-induced autoimmunity 1. SSc: an increased risk of cancer at disease onset among patients with RNA polymerase III autoantibodies; genetic abnormalities of POLR3A in cancers associated with mutation-specific T cell immune responses and cross-reactive autoantibodies
2. Dermatomyositis: striking clustering of cancer diagnosis with disease onset; an increased risk of CAM in patients with unique autoantibodies (NXP-2 and TIF-1 gamma); clinical improvement in DM with cancer therapy
Immunotherapy or chemotherapy 1. IL-2 therapy or immune checkpoint inhibitors: inflammatory arthritis and other autoimmune phenomena have been reported
2. Bleomycin and gemcitabine: associated with skin sclerosis, development of exacerbation of Raynaud's and ischemic digits
Radiation therapy Localized scleroderma may develop in radiation port
Shared etiology
Common inciting exposure Silica, solvents, organic chemicals, pesticides, smoking, infections, and hormonal state
Shared genetic susceptibility Increased risks of Hodgkin's lymphoma in patients with a personal or family history of multiple autoimmune conditions

In addition to disease activity and damage, antirheumatic disease therapies may increase the risk of subsequent malignancy. In particular, cyclophosphamide is an alkylating agent that causes cross-linking of DNA strands, thereby impeding cell division and resulting in apoptosis [18]. Acrolein, a metabolite of cyclophosphamide, is excreted by the kidneys and concentrated in the urine. This is considered to cause bladder toxicity including cystitis and cancer. Additional data on cancer risk with cyclophosphamide use are mixed due to varying diseases under study, route of drug administration, dosing, and duration of therapy [18]. However, studies have demonstrated that higher cumulative doses, an oral route of administration, and current or former smoking all associate with a higher risk of subsequent cancer [18] and [19]. Data on cancer risk with mycophenolate mofetil is less clear as most of the available data stem from the transplant literature where patients are on multiple concomitant immunosuppressive therapies [20], [21], [22], and [23]. Some studies suggest an increased risk of nonmelanoma skin cancers and lymphomas, whereas others do not. Recent data suggest that primary central nervous system (CNS) lymphoma risk may be increased in particular with mycophenolate use [24]. The risk of nonmelanoma skin cancer is likely increased in patients with RA who are treated with tumor necrosis factor (TNF) inhibitors, and some studies suggest that the risk may also be increased for melanoma [25], [26], [27], and [28]. Annual total body skin examination and counseling about sunscreen use is recommended in this patient population.

Immune dysregulation from the disease or immunosuppressive therapies could also influence the ability to clear oncogenic infections. In a large study of 576 SLE patients, the risk of virus-associated cancers was elevated (SIR 2.9), and this was noted in particular with human papillomavirus (HPV)-associated malignancies including anal cancer (SIR 26.9), vaginal/vulvar cancer (SIR 9.1), cervical dysplasia/CIS (SIR 1.8), and nonmelanoma skin cancers (SIR 2.0) [29]. The risk was also elevated for other potential virally associated cancers, including liver cancer (hepatitis B and C viruses), bladder cancer (polyoma virus), and non-Hodgkin's lymphoma (NHL; Epstein–Barr virus, EBV) [29].

While most studies investigating the link between rheumatic diseases and cancer have focused on malignancies developing after rheumatic disease onset, it is important to note that some patients develop clinical manifestations of autoimmunity shortly after a diagnosis of cancer. This raises the question of whether anticancer therapies increase the risk of developing autoimmune diseases. For example, bleomycin and gemcitabine have been reported as potential triggers of skin sclerosis and development or exacerbation of Raynaud's phenomenon and ischemic digits [30], [31], [32], [33], and [34]. Chemotherapeutic agents may cause direct vascular toxicity and neurotoxicity, thus potentially resulting in endothelial dysfunction and aberrant sympathetic arterial vasoconstriction [35]. Arthralgias, myalgias, lupus or RA-like syndromes, and reactive arthritis may also develop with various anticancer therapies [35]. Increasingly, a wide array of immunotherapies, such as interleukin (IL)-2 therapy used for malignant melanoma and renal cell carcinoma, antitumor T cell infusions, cancer vaccines, and immune checkpoint inhibitors, are being used for cancer treatment. These agents prime and amplify the host immune response to destroy neoplastic cells, and of the development of new autoimmune diseases and disease exacerbations in patients with previously quiescent rheumatic disease after exposure to immunotherapy agents has been reported [36], [37], [38], [39], [40], and [41]. As these drugs are increasingly being studied in clinical trials, it is likely that rheumatologists will see more patients where this mechanism of action is a concern. Lastly, radiation therapy may trigger severe skin thickening in patients with preexisting SSc or newly developed localized scleroderma [42] and [43].

A subset of patients may have cancer-induced autoimmunity with the diagnosis of cancer shortly preceding or following the first signs of the rheumatic illness [1]. The two best examples of this are dermatomyositis and SSc (latter example discussed in detail subsequently). In both diseases, patients have (i) an increased risk of cancer, (ii) a striking temporal relationship between cancer diagnosis and rheumatic disease onset, (iii) particular autoantibody subsets that associate with cancer at the time of rheumatic disease onset (e.g., anti-RNA polymerase III in SSc and anti-NXP2 and anti-TIF1 gamma in dermatomyositis), and (iv) an increased expression of disease-associated antigens in cancer tissues [∗1], [∗44], [45], [46], [47], and [∗48]. In dermatomyositis, the course of the disease also parallels the course of the cancer, with remission of dermatomyositis following an effective cancer therapy and relapse of dermatomyositis heralding cancer relapse. Case reports of patients with concurrent cancer and SSc also suggest that cancer therapy may be an effective antirheumatic disease therapy [49] and [50].

In addition to these possibilities, patients may have a shared genetic susceptibility to develop both cancer and autoimmune disease, or a common inciting exposure could trigger both diseases [51]. Further studies are required to define the role of genetics and environmental exposures in the association between cancer and autoimmunity.

Recent investigations have provided compelling evidence that the link between cancer and autoimmune rheumatic diseases may indeed be bidirectional in nature. Here, we review more detailed data on two of these potential mechanisms, development of inflammation-induced cancer and cancer-induced autoimmunity, through the lens of SLE and SSc.

Inflammation-induced cancer: the example of SLE

Inflammation-induced malignancy has been appreciated for many years. However, the precise pathways underlying the transformation from benign inflammation to malignancy are not fully understood. Recent data have suggested that there is a slight but significant increased risk of overall malignancy in individuals with SLE compared to the healthy controls [3]. Altered cancer risk profiles in SLE are possibly due to both environmental and intrinsic dysregulation of immunity. Both epidemiologic and epigenetic data show a clear association between the presence of inflammatory cytokines and malignancy [8] and [52]. Drawing from multiple clinical examples, we now know that uncontrolled hepatic inflammation from viral hepatitis clearly increases the risk of hepatocellular carcinoma, similar to the increase in the risk of gastric cancer due to persistent Helicobacter pylori gastritis [53]. In the case of SLE, hematologic malignancies represent the greatest incident malignancy risk [∗3] and [∗54].

Using a large, multicenter, and international cohort, Bernatsky et al. observed that the incidence and mortality of all hematologic malignancies were significantly elevated in SLE patients compared to the general population (standardized incidence ratio, SIR 3.02; 95% confidence interval, CI 2.48–3.63; and standardized mortality ratio, SMR 2.8; 95% CI, 1.2–5.6) [3]. Similarly, a meta-analysis of five prospective cohort studies published between 2002 and 2013 also showed an increased risk of hematologic malignancy in SLE patients with a pooled SIR of 2.9 (95% CI, 2.0–4.4) [55]. Among the hematologic malignancies, NHL showed the greatest association (SIR 5.7; 95% CI, 3.6–9.1) [55]. The most common type of NHL in SLE is diffuse large B cell lymphoma (DLBCL), which can be further categorized into germinal center B cell-like (GCB) and non-GCB (or activated B cell-like) lymphoma [56]. Preliminary evidence suggests that the non-GCB cell-of-origin DLBCL is more common in SLE, implying that lymphoma development in SLE and other autoimmune diseases may be secondary to chronic inflammatory stimulation [57]. Given that the incidence of malignancy is relatively rare, and in the context of long lead time, epidemiologic studies represent an interesting modality to study malignancy in autoimmune disease. In addition to the studies mentioned earlier, longitudinal epidemiologic studies have also been able to identify an increased risk of pulmonary, hepatic, and thyroid cancers in SLE, while the risk of breast and prostate cancers is reduced [58].

The precise pathways linking inflammation and malignancy in SLE are not completely understood. However, an important candidate pathway in the development of hematologic malignancy in SLE includes B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), inflammatory cytokines which promote B cell activation and contribute to disease activity in SLE [59] and [60]. This pathway may also be implicated in the pathophysiology of hematologic malignancies. BAFF and APRIL (which belong to the TNF superfamily) are associated with the activation of nuclear factor kappa B (NF-κB). NF-κB is a group of nuclear transcription factors that control many cellular processes, including inhibition of cellular apoptosis and maintenance of cell survival [61]. Over the years, NF-κB has been implicated in the tumorigenesis of many types of cancer, including hematologic, breast, and gastric cancers [53] and [61]. After staining for APRIL expression in lymphoma biopsies from individuals with RA, SLE, and control cases, Lofstrom et al. were able to demonstrate a high expression of APRIL only in SLE-associated lymphoma cases (odds ratio (OR) 23.6, 95% CI 2.4–231.2) [62]. In addition, EBV in the lymphoma tissue was significantly associated with an elevated APRIL expression [62]. The identification of EBV in SLE-associated lymphomas also underlines the potential environmental risk factors which may contribute to malignancy development in inflammatory states. In particular, EBV, which is known to be implicated in the etiology of various hematologic malignancies, has been repeatedly investigated in the SLE patients [63] and [64]. In a recent meta-analysis, EBV antiviral capsid antigen was significantly associated with SLE, supporting the hypothesis that EBV infection may predispose to the development of SLE [65] and potentially explain some of the increased lymphoma risk in SLE patients. However, despite certain case reports citing an association between immunosuppression and EBV in autoimmune conditions [66], larger population-based studies have failed to demonstrate a clear association between lymphoma and EBV in inflammatory diseases [67], and this remains an active area of research.

Cancer-induced autoimmunity: the example of SSc

In many rheumatic diseases, subsets of patients are diagnosed with a malignancy around the time of clinical onset of the rheumatic disease, raising the question of whether autoimmunity is triggered by an underlying cancer. While this has been most notable in dermatomyositis [68], [69], and [70], a similar pattern of contemporaneous cancer has been observed in SSc, particularly in patients with breast cancer, although other tumor types may be observed [46] and [71]. In an initial study of 23 patients with SSc and cancer from the Johns Hopkins Scleroderma Center cohort, patients with RNA polymerase III autoantibodies were found to have a striking clustering of cancer around the time of SSc onset, and this temporal relationship was not detected in patients with anti-centromere or anti-topoisomerase 1 antibodies [48]. These patients had unique nucleolar RNA polymerase III expression in their cancerous tissues, suggesting an association between tumor autoantigen expression and SSc-specific immune responses [48]. The increased risk of cancer within a short interval of SSc onset among patients with RNA polymerase III autoantibodies has now been confirmed in multiple international SSc cohorts [46], [47], [72], and [73]. In an Australian SSc cohort of 451 patients (64 (14.2%) with cancer), patients with RNA polymerase III autoantibodies had a 4.2-fold (95% CI 1.3, 13.4) increased risk of cancer within 5 years of SSc onset [73]. A UK SSc cohort of 2177 patients (154 (7.1%) with cancer) identified a 5.83-fold (95% CI 3.11, 10.92) increased risk of cancer within 3 years of SSc onset in patients with RNA polymerase III autoantibodies compared to those negative for these antibodies [46]. Similarly, in a study of 1044 patients at the Johns Hopkins Scleroderma Center (168 (16.1%) with cancer), a 5.08-fold (95% CI 1.60, 16.1) increased risk of cancer within 2 years of SSc onset was confirmed in patients with RNA polymerase III autoantibodies [47]. Each of these studies demonstrates the power of large observational cohort studies with long-term follow-up data to probe the complex relationship between cancer and autoimmunity in rare rheumatic diseases.

In addition to investigating the epidemiologic associations between cancer and autoimmunity, these cohorts provide rich resources to study the biological links between cancer and autoimmunity. In the Johns Hopkins cohort, cancer tissue specimens and blood samples (including serum, DNA, and peripheral blood mononuclear cells) were coupled with comprehensive clinical data to perform mechanistic studies based on the initial epidemiologic findings. This work demonstrated that genetic abnormalities (either somatic mutations and/or loss of heterozygosity) in POLR3A, the gene that encodes for RNA polymerase III, were uniquely present in cancers from patients with SSc and RNA polymerase III antibodies [74]. Patients with somatic mutations in POLR3A had mutation-specific T cell immune responses along with the development of cross-reactive RNA polymerase III autoantibodies [74]. These data suggest that altered RNA polymerase III proteins in cancers can serve as immunogens, which trigger an initial antitumor immune response that later becomes cross-reactive, thus resulting in the development of autoimmunity in SSc [1]. Data in dermatomyositis suggest that a similar mechanism may be observed in other rheumatic diseases. In one investigation, myositis autoantigens were highly expressed in cancer types associated with myositis and in regenerating myoblasts in myositis muscle [44]. Therefore, while malignancies may serve as an antigen source that initiates the immune response, regenerating cells in target tissues may be an antigen source that propagates and sustains autoimmunity [1].

As rheumatologists, we are confronted with the challenges of identifying and treating patients with concomitant cancer and autoimmunity. Cancer screening is often in the purview of the rheumatologist for patients with autoimmune rheumatic diseases, but may be neglected in the context of managing complex, multi-organ disease. Furthermore, once a cancer is identified, there are limited data to guide how the presence of a rheumatic disease should alter cancer management, or how a cancer diagnosis should modify antirheumatic therapy. Longitudinal cohort studies can play a critical role in investigating these intertwined relationships between malignancy and autoimmunity in rare rheumatic diseases.

To date, observational cohorts have enabled investigators to define whether specific rheumatic diseases are associated with an increased risk of individual tumor sites by comparing these data to those of regional cancer registries. While the majority of these studies have been conducted based on patient-reported cancer diagnoses, substantial misclassification and underestimation of cancer risk may occur. In one study of SSc patients, the sensitivity of self-reported cancer diagnoses was only 35% [75]. While patient-reported cancer diagnosis may aid in data capture, it is important to validate all cancer diagnoses with a careful review of pathology reports or oncology records. Collecting information about histology also enables one to probe more deeply than is possible with only tumor sites, as there is substantial heterogeneity in tumor characteristics and prognosis within an individual cancer site (i.e., outcomes in breast invasive ductal carcinoma vs. ductal carcinoma in situ differ). Careful planning in the study design and statistical analysis is also required to address potential bias. For instance, survival bias may be a concern in patients with concurrent malignancy and the onset of autoimmune disease, as patients must survive to presentation at a tertiary referral center and cohort entry. Factors such as left truncation, where someone is at risk but not yet seen, should be accounted for in statistical analyses.

In addition to identifying specific tumor sites of risk, it is critical to define unique rheumatic clinical phenotypes and serologic profiles that may be markers of cancer risk, as these types of epidemiologic studies lay the foundation for the study of risk stratification and targeted cancer screening. While cancer screening algorithms have been proposed in some of the rheumatic diseases [51], there is a major unmet requirement for the development of evidence-based cancer screening recommendations that factor in disease-specific phenotypic risk factors for particular tumor sites. For example, more frequent pap smears, or urine cytology screening as suggested by Tessier-Cloutier et al., may play a role in SLE patients exposed to cyclophosphamide [76]. In addition, given an increased incidence of lung cancer in many of the rheumatic diseases, low-dose computed tomography (CT) screening for lung cancer, such as that employed in patients with a significant smoking history, is another concept which may eventually be considered [77]. In patients with SSc and dermatomyositis who show unique immune responses that are associated with cancer at disease onset, more aggressive cancer screening may be warranted [51]. In addition to the direct inflammatory consequences of these diseases, part of a patient's screening and treatment should also include consideration of his/her individual cancer risk profile, including age, gender, environmental exposures, and family history. As with all cancer screening, care will be needed to ensure that the proposed interventions result in meaningful risk reduction while minimizing harm.

In addition to the study of these critically important clinical questions, large prospective cohorts that capture detailed clinical data coupled with blood, cancer, and target tissue samples also provide a rich resource to study the potential mechanisms linking cancer with autoimmunity. For patient subsets where cancer-induced autoimmunity is suspected based on this biological work, it will be important to define whether early cancer detection improves both cancer and rheumatic disease outcomes, and in particular, whether cancer therapies may also be effective antirheumatic therapies.


Studying the bidirectional relationship between cancer and relatively infrequent autoimmune rheumatic diseases is complex given the heterogeneity in rheumatic clinical phenotypes, cancer sites at risk, and oncology and rheumatology treatment exposures. In the coming years, it will be important to harness longitudinal cohorts to define patient subsets who would benefit from targeted cancer screening and risk factor modification, and to identify appropriate oncologic and rheumatic treatment approaches when these diseases coexist. Investigation of shared biological mechanisms between cancer and autoimmunity may be promising, as it may provide critical insights into the optimal treatment of both malignancy and rheumatic diseases.

Practice points
  • In many autoimmune rheumatic diseases, there is an increased risk of cancer compared to the general population. While the reasons for this increased risk have not been elucidated, it is believed that chronic inflammation and damage from the rheumatic disease or its therapies may trigger malignant transformation; conversely, antitumor immune responses targeting cancers may become cross-reactive resulting in autoimmunity.
  • Longitudinal observational studies have helped quantify the extent of cancer risk in autoimmune rheumatic disease populations. Certain cancers, including hematological malignancies such as lymphoma, are more common in several distinct autoimmune rheumatic diseases (such as RA and systemic lupus), thereby suggesting the possibility of shared biological links.
  • Some studies have been conducted to define optimal strategies to screen for and treat underlying cancer in autoimmune rheumatic diseases, but knowledge gaps remain.
Research agenda
  • The identification of patient subsets at a heightened risk for malignancy has created a need for the development of evidence-based cancer screening algorithms that factor in tumor sites at risk, unique rheumatic clinical phenotypes that may be markers of cancer, and individual cancer risk profiles based on age, gender, family history, and environmental exposures.
  • Further studies are required to define whether early cancer detection and treatment improves not only cancer, but also rheumatic diseases outcomes.
  • Coupling biological samples with careful phenotyping of patients with systemic inflammatory rheumatic illness will enable investigators to probe mechanisms linking cancer and autoimmunity.

Conflict of interest and funding statement

The authors have no conflicts of interest to disclose. This work was supported in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR061439) of the National Institutes of Health under Award Number K23 AR061439. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


  • ∗[1] A.A. Shah, L. Casciola-Rosen, A. Rosen. Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol. 2015;67(2):317-326 Crossref
  • [2] T.A. Simon, A. Thompson, K.K. Gandhi, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212 Crossref
  • ∗[3] S. Bernatsky, R. Ramsey-Goldman, J. Labrecque, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-135 Crossref
  • [4] A. Onishi, D. Sugiyama, S. Kumagai, A. Morinobu. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913-1921 Crossref
  • [5] Z. Yang, F. Lin, B. Qin, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-291 Crossref
  • [6] Y. Liang, Z. Yang, B. Qin, R. Zhong. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-1156 Crossref
  • [7] W. Shang, Y. Ning, X. Xu, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016 Crossref
  • [8] F. Balkwill, A. Mantovani. Inflammation and cancer: back to Virchow?. Lancet. 2001;357(9255):539-545 Crossref
  • [9] E. Baimpa, I.J. Dahabreh, M. Voulgarelis, H.M. Moutsopoulos. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88(5):284-293 Crossref
  • [10] C. Baldini, P. Pepe, N. Luciano, et al. A clinical prediction rule for lymphoma development in primary Sjogren's syndrome. J Rheumatol. 2012;39(4):804-808 Crossref
  • [11] E. Theander, L. Vasaitis, E. Baecklund, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis. 2011;70(8):1363-1368 Crossref
  • [12] J. Llorca, M.J. Lopez-Diaz, C. Gonzalez-Juanatey, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-38 Crossref
  • [13] K. Hellgren, A. Iliadou, R. Rosenquist, et al. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case–control study. Ann Rheum Dis. 2010;69(4):654-659 Crossref
  • [14] M. Peters-Golden, R.A. Wise, M. Hochberg, et al. Incidence of lung cancer in systemic sclerosis. J Rheumatol. 1985;12(6):1136-1139
  • [15] M. Abu-Shakra, F. Guillemin, P. Lee. Cancer in systemic sclerosis. Arthritis Rheum. 1993;36(4):460-464 Crossref
  • [16] R.K. Bobba, J.S. Holly, T. Loy, M.C. Perry. Scar carcinoma of the lung: a historical perspective. Clin Lung Cancer. 2011;12(3):148-154 Crossref
  • [17] Y.Y. Yu, P.F. Pinsky, N.E. Caporaso, et al. Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial. Arch Intern Med. 2008;168(21):2326-2332 discussion 32 Crossref
  • [18] P.A. Monach, L.M. Arnold, P.A. Merkel. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9-21 Crossref
  • [19] M. Faurschou, I.J. Sorensen, L. Mellemkjaer, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100-105
  • [20] W. Bichari, M. Bartiromo, H. Mohey, et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transpl Proc. 2009;41(2):672-673 Crossref
  • [21] J.D. Brewer, O.R. Colegio, P.K. Phillips, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol. 2009;145(12):1391-1396
  • [22] R. Marcen, C. Galeano, A. Fernandez-Rodriguez, et al. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. Transpl Proc. 2010;42(8):3055-3057 Crossref
  • [23] R. Robson, J.M. Cecka, G. Opelz, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transpl. 2005;5(12):2954-2960 Crossref
  • [24] G.M. Crane, H. Powell, R. Kostadinov, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849-33866
  • [25] F. Wolfe, K. Michaud. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886-2895 Crossref
  • [26] L.K. Mercer, A.C. Green, J.B. Galloway, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2012;71(6):869-874 Crossref
  • [27] G. Moulis, A. Sommet, J. Bene, et al. Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One. 2012;7(11):e48991 Crossref
  • [28] S. Ramiro, C. Gaujoux-Viala, J.L. Nam, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):529-535 Crossref
  • [29] L. Dreyer, M. Faurschou, M. Mogensen, S. Jacobsen. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum. 2011;63(10):3032-3037 Crossref
  • [30] C.C. Berger, C. Bokemeyer, M. Schneider, et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31A(13–14):2229-2238 Crossref
  • [31] D. Bessis, B. Guillot, E. Legouffe, J.J. Guilhou. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73-S76
  • [32] M.E. Clowse, F.M. Wigley. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol. 2003;30(6):1341-1343
  • [33] I.S. Cohen, M.B. Mosher, E.J. O'Keefe, et al. Cutaneous toxicity of bleomycin therapy. Arch Dermatol. 1973;107(4):553-555 Crossref
  • [34] W.R. Finch, G.P. Rodnan, R.B. Buckingham, et al. Bleomycin-induced scleroderma. J Rheumatol. 1980;7(5):651-659
  • [35] A. Alias, E.J. Rodriguez, H.E. Bateman, et al. Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastictherapy. Bull NYU Hosp Jt Dis. 2012;70(2):109-114
  • [36] Y. Ioannou, D.A. Isenberg. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-1442 Crossref
  • [37] Y. Bronstein, C.S. Ng, P. Hwu, W.J. Hwu. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol. 2011;197(6):W992-W1000
  • [38] M.M. Chan, R.F. Kefford, M. Carlino, et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015;38(1):37-39 Crossref
  • [39] B.L. Goldstein, L. Gedmintas, D.J. Todd. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol. 2014;66(3):768-769 Crossref
  • [40] S. Sheik Ali, A.L. Goddard, J.J. Luke, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol. 2015;151(2):195-199 Crossref
  • [41] M. Yoshioka, N. Kambe, Y. Yamamoto, et al. Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol. 2015;42(10):1008-1009
  • [42] G.B. Colver, A. Rodger, P.S. Mortimer, et al. Post-irradiation morphoea. Br J Dermatol. 1989;120(6):831-835 Crossref
  • [43] J. Varga, U.F. Haustein, R.H. Creech, et al. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA. 1991;265(24):3292-3295 Crossref
  • ∗[44] L. Casciola-Rosen, K. Nagaraju, P. Plotz, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005;201(4):591-601 Crossref
  • [45] D.F. Fiorentino, L.S. Chung, L. Christopher-Stine, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum. 2013;65(11):2954-2962 Crossref
  • [46] P. Moinzadeh, C. Fonseca, M. Hellmich, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther. 2014;16(1):R53 Crossref
  • [47] A.A. Shah, L.K. Hummers, L. Casciola-Rosen, et al. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol. 2015;67(4):1053-1061 Crossref
  • ∗[48] A.A. Shah, A. Rosen, L. Hummers, et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 2010;62(9):2787-2795 Crossref
  • [49] M. Hasegawa, S. Sato, H. Sakai, et al. Systemic sclerosis revealing T-cell lymphoma. Dermatology. 1999;198(1):75-78 Crossref
  • [50] M. Juarez, R. Marshall, C. Denton, R. Evely. Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. Rheumatology. 2008;47(11):1734-1735 Crossref
  • [51] A.A. Shah, L. Casciola-Rosen. Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol. 2015;27(6):563-570
  • [52] A. Mantovani, P. Allavena, A. Sica, F. Balkwill. Cancer-related inflammation. Nature. 2008;454(7203):436-444 Crossref
  • [53] M. Karin, T. Lawrence, V. Nizet. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124(4):823-835 Crossref
  • ∗[54] S. Bernatsky, R. Ramsey-Goldman, L. Joseph, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138-142 Crossref
  • [55] E. Apor, J. O'Brien, M. Stephen, J.J. Castillo. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Leuk Res. 2014;38(9):1067-1071 Crossref
  • [56] S. Bernatsky, R. Ramsey-Goldman, R. Rajan, et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(10):1507-1509 Crossref
  • [57] B. Tessier Cloutier, P. Farinha, S. Bernatsky, et al. Cell of origin of diffuse large B-cell lymphoma (DLBCL) in patients with systemic lupus erythematosus (SLE). Arthritis Rheumatol. 2015;67(Suppl. 10) [abstract]
  • [58] G.C. Goobie, S. Bernatsky, R. Ramsey-Goldman, A.E. Clarke. Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol. 2015;27(5):454-460 Crossref
  • [59] W. Stohl. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2014;18(4):473-489 Crossref
  • [60] E. Zollars, H. Fang, J. Bienkowska, et al. Only BAFF mRNA, not BAFF protein level in blood, is associated with SLE activity over one year. Arthritis Rheumatol. 2013;65(Suppl. 10) [abstract]
  • [61] M. Karin, Y. Cao, F.R. Greten, Z.W. Li. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301-310 Crossref
  • ∗[62] B. Lofstrom, C. Backlin, T. Pettersson, et al. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol. 2011;38(9):1891-1897 Crossref
  • [63] A.H. Draborg, K. Duus, G. Houen. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol. 2013;2013:535738
  • [64] N.S. Rasmussen, A.H. Draborg, C.T. Nielsen, et al. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand J Rheumatol. 2015;44(2):143-149 Crossref
  • [65] P. Hanlon, A. Avenell, L. Aucott, M.A. Vickers. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther. 2014;16(1):R3 Crossref
  • [66] O.W. Kamel, M. van de Rijn, M.M. Hanasono, R.A. Warnke. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma. 1995;16(5–6):363-368
  • [67] E. Baecklund, A. Iliadou, J. Askling, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692-701 Crossref
  • [68] C.L. Hill, Y. Zhang, B. Sigurgeirsson, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96-100 Crossref
  • [69] R. Buchbinder, A. Forbes, S. Hall, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134(12):1087-1095 Crossref
  • [70] D. Zantos, Y. Zhang, D. Felson. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994;21(10):1855-1859
  • [71] M. Colaci, D. Giuggioli, C. Vacchi, et al. Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmun Rev. 2014;13(2):132-137 Crossref
  • [72] P. Airo, A. Ceribelli, I. Cavazzana, et al. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol. 2011;38(7):1329-1334 Crossref
  • [73] M. Nikpour, P. Hissaria, J. Byron, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther. 2011;13(6):R211 Crossref
  • ∗[74] C.G. Joseph, E. Darrah, A.A. Shah, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-157 Crossref
  • [75] M. Hudson, A. Sharma, J. Bernstein, et al. Validity of self-reported comorbidities in systemic sclerosis. J Rheumatol. 2009;36(7):1477-1480 Crossref
  • [76] B. Tessier-Cloutier, A.E. Clarke, R. Ramsey-Goldman, et al. Systemic lupus erythematosus and malignancies: a review article. Rheum Dis Clin North Am. 2014;40(3):497-506 viii Crossref
  • [77] L.L. Humphrey, M. Deffebach, M. Pappas, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US preventive services task force recommendation. Ann Intern Med. 2013;159(6):411-420 Crossref


a Resident Internal Medicine, McGill University, Royal Victoria Hospital, Glen Site, Rm D05.5840, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada

b Division of Clinical Epidemiology, McGill University Health Center, 687 Pine Avenue, V Building, Montreal, QC H3A 1A1, Canada

c Johns Hopkins Scleroderma Center, 5501 Hopkins Bayview Circle, Room 1B.15, Baltimore, MD 21224, USA

Corresponding author. Tel.: +1 410 550 7715; fax: +1 410 550 1363.

1 Tel.: +1 514 934 8292; fax: +1 514 934 8293.

Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre.

Clinical Rheumatology

Journal cover clinical Rheumatoloy - Elsevier Resource Centre

Spread the word

If you like this resource centre, please share it.